Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Retrospective Data Show Potential Safety of Enfortumab Vedotin in Older Patients With Urothelial Carcinoma

March 2nd 2025

A retrospective study revealed that enfortumab vedotin did not produce excessive toxicity in older patients with urothelial carcinoma.

Analyses Show Effects of Treatment, Patient Location on HRQOL in Bladder and Prostate Cancer

March 1st 2025

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Efficacy and Safety of Nadofaragene Firadenovec Hold Up in NMIBC Real-World Study

February 27th 2025

The intravesical therapy nadofaragene firadenovec yielded a 79% 3-month CR rate in patients with CIS with or without papillary disease in a real-world study.

Dr Daneshmand on Using TAR-200 to Address Unmet Needs in BCG-Unresponsive NMIBC

February 25th 2025

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Dr Garje on Clinical Outcomes With Multimodal Approaches in Invasive Primary Urethral Cancer

February 24th 2025

Rohan Garje, MD, discusses clinical outcomes among patients with invasive primary urethral cancer based on varying treatment approaches and histology.

Dr Daneshmand on Findings From the SunRISE-1 Trial of TAR-200 in BCG-Unresponsive NMIBC

February 24th 2025

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal

February 24th 2025

Sia Daneshmand, MD, discusses how TAR-200 addresses an unmet need for patients with BCG-unresponsive, high-risk NMIBC.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

Detalimogene Voraplasmid Produces Complete Responses in BCG-Unresponsive NMIBC With CIS

February 19th 2025

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC

February 18th 2025

Neoadjuvant chemotherapy and concurrent chemoradiation could represent a safe, effective bladder-sparing approach in MIBC.

Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 16th 2025

Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.

Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status

February 15th 2025

Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.

Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer

February 15th 2025

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

February 15th 2025

UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC

February 14th 2025

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions

February 14th 2025

Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.

Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma

February 14th 2025

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.